Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 10, 2021

SELL
$2.86 - $4.77 $97,574 - $162,738
-34,117 Closed
0 $0
Q4 2020

Feb 08, 2021

SELL
$3.56 - $4.86 $10,313 - $14,079
-2,897 Reduced 7.83%
34,117 $120,000
Q3 2020

Nov 09, 2020

SELL
$2.6 - $5.37 $5,608 - $11,583
-2,157 Reduced 5.51%
37,014 $148,000
Q2 2020

Aug 05, 2020

BUY
$2.01 - $4.05 $17,991 - $36,251
8,951 Added 29.62%
39,171 $106,000
Q1 2020

May 06, 2020

BUY
$1.74 - $5.98 $52,582 - $180,715
30,220 New
30,220 $63,000
Q1 2018

May 11, 2018

SELL
$7.48 - $11.53 $11,220 - $17,295
-1,500 Closed
0 $0
Q4 2017

Feb 06, 2018

SELL
$9.3 - $16.93 $45,607 - $83,024
-4,904 Reduced 76.58%
1,500 $16,000
Q3 2017

Nov 07, 2017

BUY
$11.3 - $17.23 $72,365 - $110,340
6,404
6,404 $102,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.